Navigation Links
PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
Date:12/4/2009

ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new data from the Company's anthrax vaccine program showing that its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine is structurally stable and potent after 16 months at various temperatures up to and including 55 degrees C. The data were presented by Dr. Matthew Duchars, Chief Scientific Officer for PharmAthene, during an oral session at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2009 / BARDA Industry Day.

David P. Wright, President and Chief Executive Officer of PharmAthene, commented, "These new data are very encouraging as they demonstrate that PharmAthene's lyophilized rPA could be used to provide a stable cold-chain-free vaccine, enabling us to develop a formulation which could be stored and distributed at room temperature, an important attribute for deployment in the civilian Strategic National Stockpile."

Next Generation Anthrax Vaccines

Various government agencies, including the Institute of Medicine, have acknowledged the urgent need to stockpile next-generation anthrax vaccines employing modern vaccine technology, which offer the potential for improved safety, convenience and more rapid immunity, ideally with a potential to provide protective immunity in sixty days compared to six months for the currently licensed anthrax vaccine.

As a result of this Federal requirement, a Request for Proposals (RFP) was issued by the Biomedical Advanced Research and Development Authority (BARDA) for the acquisition of 25 million doses of rPA anthrax vaccine for the Strategic National Stockpile. The Company'
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
4. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
5. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
6. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
7. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
8. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... the United States , 54 percent ... BRAF inhibitor Tafinlar for BRAF -mutation-positive unresectable ... have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current ... (42 percent and 43 percent, respectively) expects to ...
(Date:9/18/2014)... 18, 2014  KIYATEC announced today that it ... Innovation Research (SBIR) Phase II Contract from the ... institutes and centers that comprise the National Institutes ... two year award, KIYATEC will expand its 3D ... the forefront of cancer therapy strategies: 1) cancer,s ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
Breaking Medicine Technology:At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
... NORTHFIELD, Ill., Aug. 22, 2011 The latest developments ... be featured topics when more than 1,000 pathologists gather ... for the annual scientific meeting of the College ... THE Pathologists, Meeting™ will highlight advances in digital ...
... SANTA ANA, Calif., Aug. 22, 2011 Abbott (NYSE: ... expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) ... The  clear, viscous, low molecular weight dispersive ... in cataract extraction, intraocular lens (IOL) implantation, corneal transplantation, ...
Cached Medicine Technology:Pathologists Gather to Focus on Advances in Molecular Testing, Digital Imaging, and Biospecimens 2Pathologists Gather to Focus on Advances in Molecular Testing, Digital Imaging, and Biospecimens 3Abbott Receives CE Mark for Healon EndoCoat Protective Gel for Cataract Surgery 2
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay News) ... is starting to spread faster than ever, the World Health Organization ... viral infection were reported in just one week. That brings ... half of those reported in the past three weeks, the ... WHO has estimated that as many as 20,000 people could ...
(Date:9/18/2014)... Los Angeles, CA (PRWEB) September 18, 2014 ... manufacture and refine carbon dioxide, selling it to ... The largest markets for carbon dioxide are food and ... freeze products, such as fruits, vegetables or pizzas. The ... additive. Beverage manufacturers use the compound to carbonate soft ...
(Date:9/18/2014)... exercise is good for you. But new research from ... an added benefit for cancer patients undergoing chemotherapy. , ... found that combining exercise with chemotherapy shrunk tumors more ... professor in the School of Nursing and director of ... the senior author on the study, which appears in ...
(Date:9/18/2014)... WA (PRWEB) September 18, 2014 Qualis ... organizations, has published a white paper, “Advancing Primary ... of Health Information Technology.” , Authors Jeff Hummel, ... CCE provide guidance to organizations engaged in the work ... how health IT can bolster PCMH objectives, such as ...
(Date:9/18/2014)... one-day conference at the Milken Institute School of Public ... 2014 to discuss the Global Health Security Agenda (GHSA) ... this event is to invite discussion of proposed priorities ... action plans to curtail the current deadly Ebola outbreak. ... organizations and more than 50 countries have engaged in ...
Breaking Medicine News(10 mins):Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2
... Webinar: , , What: Coverity Webinar, ... 10 am PT, Where:, http://seminar2.techonline.com/registration/distrib.cgi?s=1346&d=2794 , ... the web at the, ... , Overview: , In this web seminar, ...
... Vista, LLC, a marketing,and information services firm focusing on ... Kevin Grossman, who has been with the company,for seven ... , In his new role, ... HRmarketer Services Group. Mr. Grossman will continue,to report ...
... DiseasePHOENIX, Feb. 12 Although major advances have been ... attention needs to be given to one of the ... -- the painful and often progressive condition called lymphedema, ... so much about cardiovascular disease, few physicians are familiar ...
... Md., Feb. 11 Dialysis Corporation of America (Nasdaq: ... fourth quarter and full year 2008 financial results on Thursday, ... company will also host a conference call in conjunction with ... following morning, Friday, March 6, 2009 at 10:00 AM EST. ...
... Study suggest streamlining of prescribing system to avoid ... -- Doctors often override electronic medication safety alerts ... prescribing drugs for patients, which suggests that physicians ... a U.S. study. , Researchers looked at ...
... Corporation (Nasdaq: RGEN ), a global leader ... today that the Company has received ISO 9001:2000 (ISO) ... and quality systems. ISO certification was granted for ... and related services underlying its Protein A business. ...
Cached Medicine News:Health News:Webinar Alert: Coverity Announces Verification and Validation of Medical Device Software with Static Analysis - A Review of FDA Guidance and Best Practices 2Health News:Kevin Grossman Named President of HRmarketer.com 2Health News:Vascular Experts Call for Increased Awareness of Growing Problem of Lymphedema 2Health News:Vascular Experts Call for Increased Awareness of Growing Problem of Lymphedema 3Health News:Dialysis Corporation of America Announces Fiscal Year 2008 Earnings Release Date 2Health News:Docs Override Most Electronic Drug Warnings 2Health News:Repligen Announces ISO 9001:2000 Certification 2Health News:Repligen Announces ISO 9001:2000 Certification 3
... Flexible biopsy forceps are extremely delicate ... incompetent repair source, they can easily be ... turn, damage your endoscopes. , On the ... flexible biopsy forceps can have a virtually ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
... With our factory-quality repairs, physicians know ... why more hospitals turn to Mobile Instrument ... We offer a full line of carbide ... our four-way quality control process. You'll enjoy ...
Inquire...
Medicine Products: